Free Design Audit Available - Click Here for Details

Medtronic wins FDA nod for ‘game-changing’ DBS device

Medtronic (NYSE: MDT)+ today announced FDA approval of its Percept RC deep brain stimulation system, the latest member of its Percept line of DBS devices.

The medtech giant describes the Percept RC as the first DBS sensing-enable rechargeable device. In a presentation at the J.P. Morgan Healthcare Conference earlier today, CEO Geoff Martha called it a “game-changing” device that exemplifies “how Medtronic engineers are really leading the industry in innovation, developing smaller devices and inventing sensing technology to improve therapeutic benefit.”

Medtronic officials see Percept RC — and the company’s closed-loop rechargeable Inceptiv spinal cord stimulator — expanding share in what they describe as a combined $3.3 billion DBS and SCS sector.

The Medtronic Percept family already included the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads. Sensing-enabled DBS through Percept enables physicians to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia — as well as epilepsy.

Sign up for Blog Updates